randomized_controlled_trial · 2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine
highDOI · 10.1056/nejmoa2206038PMID · 35658024Trial · nct04184622Verified
Plain-English summary
All tested tirzepatide doses produced substantially greater average weight loss than placebo, with larger reductions at higher doses.
Population
Adults with obesity or overweight plus at least one weight-related complication, without diabetes
Sample size
2539
Intervention
Tirzepatide 5 mg, 10 mg or 15 mg subcutaneously once weekly versus placebo for 72 weeks
Outcomes measured
Percentage change in body weight|At least 5 percent weight reduction|Higher weight-loss thresholds|Safety and tolerability
Key findings
Tirzepatide produced dose-dependent, sustained weight reduction substantially greater than placebo; gastrointestinal events were the most common adverse effects.
Funding & disclosures
Funded by Eli Lilly; multiple authors were employees, consultants or investigators with financial relationships involving the sponsor and other companies.
Limitations
The trial excluded diabetes and used intensive trial follow-up. Gastrointestinal adverse events and treatment discontinuation affect tolerability, and sponsor involvement is relevant.Risk of bias
Low to moderate — randomized and double-blind, with industry funding and sponsor involvement in study design and reporting.Citation
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206038
Linked peptides in the PeptiBrief database